Abstract
Background: Acute pyelonephritis (AP) and complicated urinary tract infections (cUTIs) are pooled in randomized controlled trials (RCTs) of antibiotics. We assessed whether outcomes differ between subtypes and which component of the composite endpoint drives any difference. Methods: Across 10 registrational RCTs, we estimated the AP-versus-cUTI treatment effect on the composite primary endpoint (clinical cure plus microbiologic eradication at test of cure [TOC]) using random-effects risk ratios, risk difference, odds ratio, and leave-one-out sensitivity analyses. Between-arm differences in the composite and components were correlated across trials; operative definitions and stratified-reporting practices were extracted. Results: From 5971 patients (3393 AP; 2578 other cUTI), AP showed higher cure at TOC (pooled risk ratio = 1.12; 95% CI 1.03–1.23; I2 = 82%; 95% prediction interval 0.86–1.46). Between-arm differences in the composite correlated strongly with those in microbiologic eradication (r = 0.98) but weakly with those in clinical cure (r = 0.30). In the single trial with subtype-stratified components (ADAPT-PO), the AP-versus-cUTI gap was larger in microbiologic eradication (+15.6 percentage point [pp]) than in clinical response (+3.5 pp); whether this generalizes to the remaining 9 trials could not be tested. Risk of bias was overall some concerns in 9/10 trials, mostly for missing outcome data and selection of the reported result. Conclusions: Acute pyelonephritis achieved higher cure rates at TOC than other cUTIs. Heterogeneity in operative AP/cUTI definitions and limited stratified reporting of component outcomes reduce interstudy comparability. Trials should harmonize definitions, prespecify stratification by subtype, and disclose clinical and microbiologic outcomes separately.

This publication has 20 references indexed in Scilit: